Targeting M1 muscarinic and sigma-1 receptors in Alzheimer’s disease: Reversal of pathological hallmarks and associated cognitive dysfunction in McGill-R-Thy1-APP rats March 30, 2017
Mar292017 Anavex Life Sciences to Present at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases AD/PD™ 2017 March 29, 2017
Mar152017 Anavex Life Sciences to Present at Oppenheimer 27th Annual Healthcare Conference March 15, 2017
Mar132017 Anavex Life Sciences to Present at 14th Annual BIO Asia International Conference March 13, 2017
BIO CEO & Investor Conference 2017 Panel “Designing Clinical Trials in 21st Century Cures Paradigm” February 9, 2017
Feb92017 Anavex Life Sciences’ CEO Joins BIO CEO & Investor Conference 2017 Panel “Designing Clinical Trials in 21st Century Cures Paradigm” February 9, 2017
Jan232017 Anavex Life Sciences to Present at Noble Capital Markets’ Thirteenth Annual Investor Conference January 23, 2017
Jan192017 Anavex Life Sciences Receives Grant From Rettsyndrome.org to Commence U.S. Phase 2 Trial in 2017 January 19, 2017
